Exploring the usefulness of inflammation-sensitive biomarkers to reveal potential sex differences in relation to low-grade inflammation in individuals with the metabolic syndrome

Metabolism: Clinical and Experimental

Volumn 57, Issue 9, 2008, Pages 1221-1226

  Rogowski, Ori ^a,b   Shapira, Itzhak ^a,b   Berliner, Shlomo ^a,b  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; FIBRINOGEN;

ADULT; ARTICLE; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NEUTROPHIL; PRIORITY JOURNAL; SEX DIFFERENCE;

AGED; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CROSS-SECTIONAL STUDIES; FEMALE; FIBRINOGEN; HUMANS; INFLAMMATION; LEUKOCYTE COUNT; MALE; METABOLIC SYNDROME X; MIDDLE AGED; NEUTROPHILS; SEVERITY OF ILLNESS INDEX; SEX CHARACTERISTICS;

EID: 48849114898     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2008.04.015     Document Type: Article

References (42)

1. Mikhail G.W. Coronary heart disease in women. BMJ 331 (2005) 467-468
2. Bairey M.N., Bonow R.O., Sopko G., Balaban R.S., Cannon III R.O., Gordon D., et al. Women's ischemic syndrome evaluation: current status and future research directions: report of the National Heart, Lung and Blood Institute workshop: October 2-4, 2002: executive summary. Circulation 109 (2004) 805-807
3. Dandona P., Aljada A., Chaudhuri A., Mohanty P., and Garg R. Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation 111 (2005) 1448-1454
4. Ridker P.M. High-sensitivity C-reactive protein, inflammation, and cardiovascular risk: from concept to clinical practice to clinical benefit. Am Heart J 148 (2004) S19-S26
5. Torres J.L., and Ridker P.M. Clinical use of high sensitivity C-reactive protein for the prediction of adverse cardiovascular events. Curr Opin Cardiol 18 (2003) 471-478
6. Natarajan S., Liao Y., Sinha D., Cao G., McGee D.L., and Lipsitz S.R. Sex differences in the effect of diabetes duration on coronary heart disease mortality. Arch Intern Med 165 (2005) 430-435
7. Harrington R.A. Women, acute ischemic heart disease, and antithrombotic therapy: challenges and opportunities. Circulation 115 (2007) 2796-2798
8. Norman P.E., and Powell J.T. Abdominal aortic aneurysm: the prognosis in women is worse than in men. Circulation 115 (2007) 2865-2869
9. Rogowski O., Shapira I., Shirom A., Melamed S., Toker S., and Berliner S. Heart rate and microinflammation in men: a relevant atherothrombotic link. Heart 92 (2007) 940-947
10. Berliner S., Rogowski O., Aharonov S., Mardi T., Tolshinsky T., Rozenblat M., et al. Erythrocyte adhesiveness/aggregation. A novel biomarker for the detection of low grade internal inflammation in individuals with atherothrombotic risk factors and proven vascular disease. Am Heart J 149 (2005) 260-267
11. Rogowski O., Toker S., Shapira I., Melamed S., Shirom A., Zeltser D., et al. Values of high sensitivity C-reactive protein in each month of the year in apparently healthy individuals. Am J Cardiol 95 (2005) 152-155
12. Zeltser D., Rogowski O., Berliner S., Mardi T., Justo D., Serov J., et al. Sex differences in the expression of haemorheological determinants in individuals with atherothrombotic risk factors and apparently health people. Heart 90 (2004) 277-281
13. Zeltser D., Rogowski O., Mardi T., Justo D., Tolshinsky T., Goldin E., et al. Clinical and laboratory characteristics of patients with atherothrombotic risk factors presenting with low concentrations of highly sensitive C-reactive protein. Atherosclerosis 176 (2004) 297-301
14. Steinvil A., Shapira I., Arbel Y., Justo D., Berliner S., and Rogowski O. Determinants of the erythrocyte sedimentation rate at the era of micro-inflammation, excluding individuals with elevated C-reactive protein. Am J Clin Pathol 129 (2008) 486-491
15. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106 (2002) 3143-3421
16. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
17. Genuth S., Alberti K.G., Bennett P., Buse J., Defronzo R., Kahn R., et al. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 26 (2003) 3160-3167
18. Grundy S.M., Cleeman J.I., Daniels S.R., Donato K.A., Eckel R.H., Franklin B.A., et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation 112 (2005) 2735-2752
19. International committee for standardization in hematology. Recommendation of measurement of erythrocyte sedimentation rate of human blood. Immunochemistry 2 (1965) 235-254
20. Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol Basel 17 (1957) 237-246
21. Rifai N., Tracy R.P., and Ridker P.M. Clinical efficacy of an automated high-sensitivity C-reactive protein assay. Clin Chem 45 (1999) 2136-2141
22. Lowe G.D., and Pepys M.B. C-reactive protein and cardiovascular disease: weighing the evidence. Curr Atheroscler Rep 8 (2006) 421-428
23. Kannel W.B., Wolf P.A., Castelli W.P., and D'Agostino R.B. Fibrinogen and risk of cardiovascular disease. The Framingham Study. JAMA 258 (1987) 1183-1186
24. Erikssen G., Liestol K., Bjornholt J.V., Stormorken H., Thaulow E., and Erikssen J. Erythrocyte sedimentation rate: a possible marker of atherosclerosis and a strong predictor of coronary heart disease and mortality. Eur Heart J 21 (2000) 1614-1620
25. Coller B.S. Leukocytosis and ischemic vascular disease morbidity and mortality: is it time to intervene?. Arterioscler Thromb Vasc Biol 25 (2005) 658-670
26. Gu D., Reynolds K., Wu X., Chen J., Duan X., Reynolds R.F., et al. Prevalence of the metabolic syndrome and overweight among adults in China. Lancet 365 (2005) 1398-1405
27. Rogowski O., Zeltser D., Shapira I., Burke M., Zakuth V., Mardi T., et al. Gender difference in C-reactive protein concentrations in individuals with atherothrombotic risk factors and apparently healthy ones. Biomarkers 9 (2004) 85-92
28. Rutter M.K., Meigs J.B., Sullivan L.M., D'Agostino Sr. R.B., and Wilson P.W.F. C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham Offspring Study. Circulation 110 (2004) 380-385
29. Khera A., McGuire D.K., Murphy S.A., Stanek H.G., Das S.R., Vongpatanasin W., et al. Race and gender differences in C-reactive protein levels. J Am Coll Cardiol 46 (2005) 464-469
30. Yamada S., Gotoh T., Nakashima Y., Kayaba K., Ishikawa S., Nago N., et al. Distribution of serum C-reactive protein and its association with atherosclerotic risk factors in a Japanese population: Jichi Medical School Cohort Study. Am J Epidemiol 153 (2001) 1183-1190
31. Ford E.S., Giles W.H., Mokdad A.H., and Myers G.L. Distribution and correlates of C-reactive protein concentrations among adult US women. Clin Chem 50 (2004) 574-581
32. Han T.S., Sattar N., Williams K., Gonzalez-Villalpando C., Lean M.E.J., and Haffner S.M. Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study. Diabetes Care 25 (2002) 2021
33. Nakanishi N., Shiraishi T., and Wada M. C-reactive protein concentration is more strongly related to metabolic syndrome in women than in men: the Minoh Study. Circ J 69 (2005) 386-391
34. Bo S., Gentile L., Ciccone G., Baldi C., Benini L., Dusio F., et al. The metabolic syndrome and high C-reactive protein: prevalence and differences by sex in a southern-European population-based cohort. Diabetes Metab Res Rev 21 (2005) 515-524
35. Pou K.M., Massaro J.M., Hoffmann U., Vasan R.S., Maurovich-Horvat P., Larson M.G., et al. Visceral and subcutaneous adipose tissue volumes are cross-sectionally related to markers of inflammation and oxidative stress: the Framingham Heart Study. Circulation 116 (2007) 1234-1241
36. Virdis A., Ghiadoni L., Plantinga Y., Taddei S., and Salvetti A. C-reactive protein and hypertension: is there a causal relationship?. Curr Pharm Des 13 (2007) 1693-1698
37. Mora S., and Ridker P.M. Justification for the use of statins in primary prevention: an intervention trial evaluating rosuvastatin (JUPITER)-can C-reactive protein be used to target statin therapy in primary prevention?. Am J Cardiol 97 (2006) 33A-41A
38. Ndumele C.E., Pradhan A.D., and Ridker P.M. Interrelationships between inflammation, C-reactive protein, and insulin resistance. J Cardiometab Syndr 1 (2006) 190-196
39. Iso H., Sato S., Kitamura A., Imano H., Kiyama M., Yamagishi K., et al. Metabolic syndrome and the risk of ischemic heart disease and stroke among Japanese men and women. Stroke 38 (2007) 1744-1751
40. Mega J.L., Morrow D.A., Ostor E., Dorobantu M., Qin J., Antman E.M., et al. Outcomes and optimal antithrombotic therapy in women undergoing fibrinolysis for ST-elevation myocardial infarction. Circulation 115 (2007) 2822-2828
41. Qiu H., Depre C., Ghosh K., Resuello R.G., Natividad F.F., Rossi F., et al. Mechanism of gender-specific differences in aortic stiffness with aging in nonhuman primates. Circulation 116 (2007) 669-676
42. Lakoski S.G., Cushman M., Criqui M., Rundek T., Blumenthal R.S., D'Agostino Jr. R.B., et al. Gender and C-reactive protein: data from the Multiethnic Study of Atherosclerosis (MESA) cohort. Am Heart J 152 (2006) 593-598